Anabolic - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Anabolic

The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform

Timo Seppälä – One of the best experts on this subject based on the ideXlab platform.

  • Steroid Use and Long-Term Health Risks in Former Athletes
    Sports Medicine, 2002
    Co-Authors: Miia Pärssinen, Timo Seppälä

    Abstract:

    This article focuses on Anabolic steroid adverse effects on the cardiovascular system and mental health issues as well as the possible increase in the incidence of neoplasms in Anabolic steroid users. On the basis of findings in the literature, the authors consider these three issues as the most significant concerning morbidity and mortality among Anabolic steroid users. A study by Pärssinen et al. (2000) has shown an increased incidence of premature mortality among power lifters. Anabolic steroids and other concomitantly used drugs are the probable cause of this increased mortality, as power training itself does not increase health risks and all types of physical activity promote health.

John Paul Wright – One of the best experts on this subject based on the ideXlab platform.

  • Anabolic androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the united states
    American Journal of Public Health, 2008
    Co-Authors: Kevin M Beaver, Michael G Vaughn, Matt Delisi, John Paul Wright

    Abstract:

    We examined the effects of Anabolic-androgenic steroid use on serious violent behavior. Multivariate models based on data from the National Longitudinal Study of Adolescent Health (N = 6823) were used to examine the association between lifetime and past-year self-reported Anabolic-androgenic steroid use and involvement in violent acts. Compared with individuals who did not use steroids, young adult males who used Anabolic-androgenic steroids reported greater involvement in violent behaviors after we controlled for the effects of key demographic variables, previous violent behavior, and polydrug use.

John P. Bilezikian – One of the best experts on this subject based on the ideXlab platform.

  • Combination Anabolic and antiresorptive therapy for osteoporosis: opening the Anabolic window.
    Current Osteoporosis Reports, 2008
    Co-Authors: John P. Bilezikian

    Abstract:

    Antiresorptive agents for osteoporosis are a cornerstone of therapy, but Anabolic drugs have recently increased our options. By stimulating bone formation, Anabolic agents reduce fracture incidence by improving bone qualities in addition to increasing bone mass. The only Anabolic agent currently approved for osteoporosis by the US Food and Drug Administration, teriparatide (recombinant human parathyroid hormone [1–34]), has emerged as a major approach to selected patients with osteoporosis. Recombinant human parathyroid hormone (1–84) is also available in Europe. Teriparatide increases bone density and bone turnover, improves microarchitecture, and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. A current concept in the mechanism of teriparatide action is related to its effect to stimulate processes associated with bone formation before it stimulates processes associated with bone resorption. This sequence of events has led to the concept of the Anabolic window, the period of time when teriparatide is maximally Anabolic. Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents have led to ways in which the Anabolic window can be expanded.

  • Anabolic therapy for osteoporosis.
    Women's Health, 2007
    Co-Authors: John P. Bilezikian

    Abstract:

    Antiresorptive agents for osteoporosis are a cornerstone of therapy, but Anabolic drugs have recently increased our options. By directly stimulating bone formation, Anabolic agents reduce fracture incidence by improving bone qualities as well as increasing bone mass. The Anabolic agent currently approved for osteoporosis, teriparatide (recombinant human parathyroid hormone[1-34]), has emerged as a major approach for selected patients with osteoporosis. Parathyroid hormone(1-84) is also available in Europe. Teriparatide increases bone density and bone turnover, improves microarchitecture and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. A current concept in the mechanism of teriparatide action is related to its effect of stimulating processes associated with bone formation before processes associated with bone resorption. This sequence of events has led to the concept of the Anabolic window, the period of time when teriparatide is maximally Anabolic. Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents has led to ways in which the Anabolic window can be expanded.

  • Anabolic skeletal therapy for osteoporosis
    Arquivos Brasileiros De Endocrinologia E Metabologia, 2006
    Co-Authors: Monica Girotra, Mishaela R. Rubin, John P. Bilezikian

    Abstract:

    Antiresorptive agents for osteoporosis are a cornerstone of therapy, but Anabolic drugs have recently widened our therapeutic options. By directly stimulating bone formation, Anabolic agents reduce fracture incidence by improving bone qualities besides increasing bone mass. In this article, we review the role of Anabolic treatment for osteoporosis. The only Anabolic agent currently approved in the United States for osteoporosis, teriparatide [recombinant human parathyroid hormone(1-34)], has clearly emerged as a major approach to selected patients with osteoporosis. Teriparatide increases bone density and bone turnover, improves microarchitecture, and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. Teriparatide is approved for both postmenopausal women and men with osteoporosis who are at high risk for fracture. Other potential Anabolic therapies for osteoporosis, including other forms of parathyroid hormone, strontium ranelate, growth hormone, and insulin-like growth factor-1, are also reviewed in this article.